Brukinsa (zanubrutinib) — CareFirst (Caremark)

Initial criteria

• Used as third line or subsequent therapy in combination with obinutuzumab (Gazyva).

Reauthorization criteria

• No evidence of unacceptable toxicity or disease progression while on the current regimen.

Approval duration

12 months